Neurogene Inc.

NGNE Healthcare Biotechnology

Neurogene Inc.’s revenue for fiscal 2024 (year ended December 2024) was $925,000.00. In the quarter to June 2026, EPS fell 45.7%, free cash flow fell 23.0% and total debt fell 66.7%, each against the same quarter a year earlier.

23.27 0.68 −2.84%
Market cap
$479.3M
P/E
0.0×
Fwd P/E
−4.5×
Dividend yield
—
F-score
n/a
Altman Z
8.68
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
18.39 16.56 13.08 10.64
Net Debt/EBITDA
11.13 9.87 7.40 6.23
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.93) (0.82) (1.18) (1.07)
Book value per Share
12.54 12.42 10.66 9.63
Free Cash Flow
(19.63) (17.56) (26.40) (24.11)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates